Medigen Vaccine Biologics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	613.17	605.64	389.62	365.04	3,281
Revenue Growth (YoY)	1.24%	55.44%	6.73%	-88.87%	28413.03%
Cost of Revenue	248.5	209.22	159.4	577.64	975.96
Gross Profit	364.67	396.42	230.22	-212.6	2,305
Selling, General & Admin	291.79	320.58	243.44	183.67	148.21
Research & Development	338.57	221.51	1,201	1,140	1,193
Operating Expenses	630.37	542.09	1,444	1,324	1,341
Operating Income	-265.69	-145.67	-1,214	-1,536	963.73
Interest Expense	-8.8	-18.89	-37.57	-26.89	-6.02
Interest & Investment Income	29.3	46.25	83.28	7.61	2.74
Currency Exchange Gain (Loss)	-29.33	38.35	-0.33	28.86	7.52
Other Non Operating Income (Expenses)	1.51	-1.62	8.61	32.25	-0.07
EBT Excluding Unusual Items	-273.02	-81.57	-1,160	-1,494	967.9
Gain (Loss) on Sale of Assets	-9.2	0.41	-	-	-
Other Unusual Items	0.5	0.7	-	19.86	442.36
Pretax Income	-281.71	-80.47	-1,160	-1,475	1,410
Net Income	-281.71	-80.47	-1,160	-1,475	1,410
Net Income to Common	-281.71	-80.47	-1,160	-1,475	1,410
Shares Outstanding (Basic)	329	329	328	323	319
Shares Outstanding (Diluted)	329	329	328	323	321
Shares Change (YoY)	0.03%	0.10%	1.50%	0.73%	15.82%
EPS (Basic)	-0.86	-0.24	-3.53	-4.56	4.42
EPS (Diluted)	-0.86	-0.24	-3.53	-4.56	4.39
Free Cash Flow	-99.72	6.46	-521.25	-1,353	446.26
Free Cash Flow Per Share	-0.30	0.02	-1.59	-4.18	1.39
Gross Margin	59.47%	65.45%	59.09%	-58.24%	70.25%
Operating Margin	-43.33%	-24.05%	-311.54%	-420.85%	29.37%
Profit Margin	-45.94%	-13.29%	-297.68%	-403.95%	42.98%
Free Cash Flow Margin	-16.26%	1.07%	-133.78%	-370.64%	13.60%
EBITDA	-144.21	-26.16	-1,098	-1,423	1,072
EBITDA Margin	-23.52%	-4.32%	-281.86%	-	32.67%
D&A For EBITDA	121.49	119.5	115.64	112.91	108.34
EBIT	-265.69	-145.67	-1,214	-1,536	963.73
EBIT Margin	-43.33%	-24.05%	-	-	29.37%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.